Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
about
Cancer and the metastatic substrate.Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.Genetic variants in the exon region of versican predict survival of patients with resected early-stage hepatitis B virus-associated hepatocellular carcinoma.
P2860
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
@en
type
label
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
@en
prefLabel
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
@en
P2093
P2860
P356
P1433
P1476
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
@en
P2093
Hiroaki Shiina
Hiroaki Yasumoto
Hiroshi Hirata
Masahiro Sumura
Miho Hiraki
Naoko Arichi
Rajvir Dahiya
Sigenobu Nakamura
Takeo Hiraoka
Yozo Mitsui
P2860
P304
P356
10.18632/ONCOSCIENCE.136
P577
2015-03-02T00:00:00Z